StockIQpro
NASDAQ:DNTH

Dianthus Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Dianthus Therapeutics, Inc.'s revenue fell 67.3% in fiscal 2025 to $2.0M while operating margin fell to −8739.3%, its lowest in 3 years. The diluted share count rose 15.9%.Summary generated from Dianthus Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$2.0M
Revenue growth−67.3%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−8739.3%
Net margin−7973.3%
ROICn/a
Return on equity−38.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+15.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/a362
Operating income−75−30−48−102−178
Net income−71−28−44−85−162
Free cash flow−61−29n/an/an/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations